SGMOQ · Sangamo Therapeutics, Inc · Webcasts, Transcripts & Audio

Substantial doubt about the company's ability to continue as a going concern.

“Our history of significant losses, negative cash flows from operations, negative working capital, limited liquidity resources currently on hand and dependence on our ability to obtain additional financing to fund our operations have resulted in management's assessment that there is substantial doubt about our ability to continue as a going concern for at least the next 12 months from the date the financial statements included in this Quarterly Report are issued.”